Ezetimibe | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Ezetimibe
US Patents

With Fermion, start the journey of your innovative API.

Contact Supplier

Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

Contact Supplier

dmfs-not-supported-m-2025-06-30

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

veranova-m-2025-06-30

Contact Supplier

jdmfs-not-supported-m-2025-06-30

Ezetimibe

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

130 API Suppliers, 29 USDMF, 11 JDMF, 20 EU WC, 73 KDMF, 19 NDC API, 49 Listed Suppliers, $ API Reference Price

130 API Suppliers
29 USDMF
11 JDMF
20 EU WC
73 KDMF
19 NDC API
49 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

28 Drugs in Development

28 Drugs in Development

INTERMEDIATES

27 Intermediate Suppliers

27 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

623 FDF Dossiers, 70 FDA Orange Book, 364 Europe, 20 Canada, 25 Australia, 44 South Africa, 100 Listed Dossiers

623 FDF Dossiers
70 FDA Orange Book
364 Europe
20 Canada
25 Australia
44 South Africa
100 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 10MG, TABLET;ORAL - 10MG;10MG, TABLET;ORAL - 10MG;20MG, TABLET;ORAL - 10MG;40MG, TABLET;ORAL - 10MG;80MG

TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 10MG
TABLET;ORAL - 10MG;10MG
TABLET;ORAL - 10MG;20MG
TABLET;ORAL - 10MG;40MG
TABLET;ORAL - 10MG;80MG

RELATED EXCIPIENT COMPANIES

2 Minakem, 6 SPI Pharma, 6 DKSH, 6 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 ACG Worldwide, 1 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 19 BASF, 10 Corel Pharma Chem, 7 DFE Pharma, 8 Gangwal Chemicals, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 36 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 3 Nitika Pharmaceutical Specialities, 3 Novo Excipients, 5 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 18 Roquette, 7 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

66 Fillers, Diluents & Binders, 45 Coating Systems & Additives, 40 Disintegrants & Superdisintegrants, 28 Direct Compression, 27 Granulation, 24 Controlled & Modified Release, 22 Lubricants & Glidants, 17 Thickeners and Stabilizers, 16 Co-Processed Excipients, 10 Chewable & Orodispersible Aids, 9 Taste Masking, 9 Solubilizers, 8 Film Formers & Plasticizers, 6 API Stability Enhancers, 5 Empty Capsules, 5 Coloring Agents, 5 Rheology Modifiers, 4 Parenteral, 4 Vegetarian Capsules, 4 Emulsifying Agents, 2 Topical, 1 Surfactant & Foaming Agents

66 Fillers, Diluents & Binders
45 Coating Systems & Additives
40 Disintegrants & Superdisintegrants
28 Direct Compression
27 Granulation
24 Controlled & Modified Release
22 Lubricants & Glidants
17 Thickeners and Stabilizers
16 Co-Processed Excipients
10 Chewable & Orodispersible Aids
9 Taste Masking
9 Solubilizers
8 Film Formers & Plasticizers
6 API Stability Enhancers
5 Empty Capsules
5 Coloring Agents
5 Rheology Modifiers
4 Parenteral
4 Vegetarian Capsules
4 Emulsifying Agents
2 Topical
1 Surfactant & Foaming Agents

DIGITAL CONTENT

113 News #PharmaBuzz

113 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 329 Regulatory FDF Prices, 41 Annual Reports

3 US Medicaid Prescriptions
329 Regulatory FDF Prices
41 Annual Reports

MARKET PLACE

21 APIs, 5 FDF Dossiers

21 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

19 US Patents, 3 US Exclusivities, 2 Health Canada Patents

19 US Patents
3 US Exclusivities
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 USP, 2 Others

4 USP
2 Others

ANALYTICAL

6 BioAnalytical Methods

6 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 1,179 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

19 All

01 8ALTHERA PHARMS

02 8ESPERION THERAPS INC

03 3ORGANON

filter Patent Number Reset all filters

19 All

01 17335799

02 27612058

03 49763885

04 410376470

05 210912751

06 111613511

07 211744816

08 111760714

09 111926584

10 17612058*PED

filter API Patent Reset all filters

19 All

01 2Y

02 17Blank

filter FDF Patent Reset all filters

19 All

01 9Y

02 10Blank

filter Expiration Date Reset all filters

19 All

01 22025-10-30

02 12026-04-30

03 12030-12-03

04 82033-05-01

05 42036-03-14

06 32040-06-19

Product Main Page

01

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

Discovery Europe

Not Confirmed

ALTHERA PHARMS

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 10376470

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

Discovery Europe

Not Confirmed

ALTHERA PHARMS

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 9763885

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

Discovery Europe

Not Confirmed

ALTHERA PHARMS

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 9763885

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

Discovery Europe

Not Confirmed

ALTHERA PHARMS

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 10376470

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

Discovery Europe

Not Confirmed

ALTHERA PHARMS

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 10376470

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

Discovery Europe

Not Confirmed

ALTHERA PHARMS

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 9763885

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

Discovery Europe

Not Confirmed

ALTHERA PHARMS

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 10376470

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

Discovery Europe

Not Confirmed

ALTHERA PHARMS

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 9763885

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

ESPERION THERAPS INC

BEMPEDOIC ACID; EZETIMIBE

Discovery Europe

Not Confirmed

ESPERION THERAPS INC

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-03-14

BEMPEDOIC ACID; EZETIMIBE

US Patent Number : 11744816

Drug Substance Claim :

Drug Product Claim :

Application Number : 211617

Patent Use Code : U-3883

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-03-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

ESPERION THERAPS INC

BEMPEDOIC ACID; EZETIMIBE

Discovery Europe

Not Confirmed

ESPERION THERAPS INC

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-03-14

BEMPEDOIC ACID; EZETIMIBE

US Patent Number : 10912751

Drug Substance Claim :

Drug Product Claim :

Application Number : 211617

Patent Use Code : U-3884

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-03-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!